Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

Transplantation - 27 Mar 2011

Picard Nicolas, Rouguieg-Malki Koukeb, Kamar Nassim, Rostaing Lionel, Marquet Pierre

Abstract excerpt

BACKGROUND: CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS: We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic metabolism using a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Genotype

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Polymorphism, Single Nucleotide

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 21389905
DOI: 10.1097/TP.0b013e31820ae4ac
PMCID: PMC3324087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.PMID 21389905Read ↗

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Semantic proximity Read ↗

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.Semantic proximity Read ↗

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetic biomarkers: cytochrome P450 3A5.Semantic proximity Read ↗

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.Semantic proximity Read ↗

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.Semantic proximity Read ↗

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.Semantic proximity Read ↗

Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5.Semantic proximity Read ↗

The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.Semantic proximity Read ↗

Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.Semantic proximity Read ↗

Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.Semantic proximity Read ↗

Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.